Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade Through EMT-Stromal and Tgfβ-Dependent Mechanisms

Overview

Journal Mol Cancer Ther

Date 2022 Sep 21

PMID 36129800

Authors

Haocheng Yu

John P Sfakianos

Li Wang

Yang Hu

Jorge Daza

Matthew D Galsky

Harkirat S Sandhu

Olivier Elemento

Bishoy M Faltas

Adam M Farkas

Nina Bhardwaj

Jun Zhu

David J Mulholland

Affiliations

Soon will be listed here.

Abstract

Most patients with bladder cancer do not respond to ICB targeting of the PD-L1 signaling axis. Our modeling applied a de novo resistance signature to show that tumor-infiltrating myeloid cells promote poor treatment response in a TGFβ-dependent mechanism.

Citing Articles

Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer.

Wang L, Izadmehr S, Sfakianos J, Tran M, Beaumont K, Brody R iScience. 2024; 27(6):109928.

PMID: 38812546 PMC: 11133924. DOI: 10.1016/j.isci.2024.109928.

References

Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo A . Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res. 2013; 20(6):1601-9. DOI: 10.1158/1078-0432.CCR-13-2508. View

Azizi E, Carr A, Plitas G, Cornish A, Konopacki C, Prabhakaran S . Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018; 174(5):1293-1308.e36. PMC: 6348010. DOI: 10.1016/j.cell.2018.05.060. View

Wang L, Saci A, Szabo P, Chasalow S, Castillo-Martin M, Domingo-Domenech J . EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018; 9(1):3503. PMC: 6115401. DOI: 10.1038/s41467-018-05992-x. View

Duan Z, Luo Y . Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6(1):127. PMC: 7994399. DOI: 10.1038/s41392-021-00506-6. View

Xu C, Su Z . Identification of cell types from single-cell transcriptomes using a novel clustering method. Bioinformatics. 2015; 31(12):1974-80. PMC: 6280782. DOI: 10.1093/bioinformatics/btv088. View

Yang M, McKay D, Pollard J, Lewis C . Diverse Functions of Macrophages in Different Tumor Microenvironments. Cancer Res. 2018; 78(19):5492-5503. PMC: 6171744. DOI: 10.1158/0008-5472.CAN-18-1367. View

Wang L, Sebra R, Sfakianos J, Allette K, Wang W, Yoo S . A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. Genome Med. 2020; 12(1):24. PMC: 7049190. DOI: 10.1186/s13073-020-0720-0. View

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

Jojic V, Zuk O, Sun X, Best A, Knell J, Goldrath A . Identification of transcriptional regulators in the mouse immune system. Nat Immunol. 2013; 14(6):633-43. PMC: 3690947. DOI: 10.1038/ni.2587. View

10.

Wang L, Sfakianos J, Beaumont K, Akturk G, Horowitz A, Sebra R . Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021; 27(15):4287-4300. PMC: 8338756. DOI: 10.1158/1078-0432.CCR-20-4574. View

11.

Kerzeli I, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I . Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations. PLoS One. 2021; 16(7):e0253178. PMC: 8262791. DOI: 10.1371/journal.pone.0253178. View

12.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

13.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

14.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

15.

Shu Y, Cheng P . Targeting tumor-associated macrophages for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2020; 1874(2):188434. DOI: 10.1016/j.bbcan.2020.188434. View

16.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

17.

Chang S . Re: EMT- and Stroma-Related Gene Expression and Resistance to PD-1 Blockade in Urothelial Cancer. J Urol. 2019; 202(3):458. DOI: 10.1097/01.JU.0000569196.28580.f2. View

18.

Fantini D, Glaser A, Rimar K, Wang Y, Schipma M, Varghese N . A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. 2018; 37(14):1911-1925. PMC: 5886988. DOI: 10.1038/s41388-017-0099-6. View

19.

Thomas D, Massague J . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8(5):369-80. DOI: 10.1016/j.ccr.2005.10.012. View

20.

Nagao M, Suzuki E, Yasuo K, Yahagi T, Seino Y . Mutagenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine, a bladder carcinogen, and related compounds. Cancer Res. 1977; 37(2):399-407. View